Canadian Insider

LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced that the company will present at a scientific conference and two investor conferences during the month of September.

Oligonucleotide Therapeutics Society

During the 12^th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) September 25 – 28, 2016 the company will present two posters titled: ‘QR-010 Restores CFTR Function in Models of F508del-mediated Cystic Fibrosis’ and ‘QR-110 Treatment for Leber’s Congenital Amaurosis Type 10 due to the p.Cys998X Mutation in CEP290’. The abstracts will be available on the OTS website prior to the conference. The conference is being held at the Centre Mont-Royal in Montreal, Quebec, Canada.

LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Daniel de Boer, Chief Executive Officer, will take part in an analyst led fireside chat during the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 28, 2016 at 1:35pm ET. The conference is being held at the Lotte New York Palace in New York, NY, USA.

The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 30 days following the presentation date.

Jefferies Cystic Fibrosis Summit

Daniel de Boer, Chief Executive Officer, will present at the Jefferies Cystic Fibrosis Summit on Thursday, September 29, 2016. The conference is being held at the Jefferies Conference Center in New York, NY, USA.

Further details on the presentation will be posted in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

FORWARD-LOOKING STATEMENTS 

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements about the OTS conference, Leerink Partners roundtable and Jefferies CF Summit. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

ProQR Therapeutics N.V.:
Sariette Witte
Head of Communications
T: +1 213 261 8891
[email protected]